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Multipotent stromal cells (MSCs) and their osteo-
blastic lineage cell (OBC) derivatives are part of the
bone marrow (BM) niche and contribute to hemato-
poietic stem cell (HSC) maintenance. Here, we
show that myeloproliferative neoplasia (MPN) pro-
gressively remodels the endosteal BM niche into a
self-reinforcing leukemic niche that impairs normal
hematopoiesis, favors leukemic stem cell (LSC) func-
tion, and contributes to BM fibrosis. We show that
leukemic myeloid cells stimulate MSCs to overpro-
duce functionally altered OBCs, which accumulate
in the BM cavity as inflammatory myelofibrotic cells.
We identify roles for thrombopoietin, CCL3, and
direct cell-cell interactions in driving OBC expan-
sion, and for changes in TGF-b, Notch, and inflam-
matory signaling in OBC remodeling. MPN-
expanded OBCs, in turn, exhibit decreased expres-
sion of many HSC retention factors and severely
compromised ability to maintain normal HSCs, but
effectively support LSCs. Targeting this pathological
interplay could represent a novel avenue for treat-
ment of MPN-affected patients and prevention of
myelofibrosis.
INTRODUCTION
Hematopoietic stem cells (HSCs) sustain the life-long production
of all types of mature blood cells (Orkin and Zon, 2008). At steady
state, HSCs primarily reside in the bone marrow (BM) cavity,
where they interact with different types of stromal cells ex-
pressing important regulatory molecules including stem cell
factor (SCF), C-X-C motif chemokine 12 (CXCL12, also called
SDF1a), and transforming growth factor b (TGF-b) (Frenette
et al., 2013). Although early mouse studies implicated mature
bone-forming osteoblasts (Calvi et al., 2003), recent work hasCell Srefined the identity of HSC-supportive cells to several popula-
tions of multipotent stromal cells (MSCs) and their early osteo-
blastic lineage cell (OBC) derivatives. Both Runx2-expressing
OBCs (Chitteti et al., 2010) and perivascular MSC-like cells ex-
pressing either nestin (Nes) (Me´ndez-Ferrer et al., 2010), high
levels of CXCL12 (so-called Cxcl12-abundant reticular cells, or
CAR cells) (Omatsu et al., 2010), or leptin receptor (Lepr) (Ding
et al., 2012) have been shown to be important for HSC mainte-
nance. However, not all MSC derivatives have HSC-supportive
activity, and, in fact, mature adipocytes negatively impact HSC
function (Naveiras et al., 2009). Other known HSC-supporting
BM niche cells include endothelial cells (ECs) (Doan and Chute,
2012) and ectodermally derived nonmyelinating Schwann cells
(Yamazaki et al., 2011). Therefore, the emerging picture of the
HSC BM niche is a complex array of regulatory cell types with
a predominant role for MSCs and their early OBC derivatives in
forming both perivascular end endosteal BM niches that main-
tain HSCs and regulate blood production.
Deregulation of HSC activity is an important step in the devel-
opment of myeloid malignancies (Passegue´ et al., 2003). This is
particularly the case for myeloproliferative neoplasms (MPNs), a
class of clonal disorders that are propagated by leukemic stem
cells (LSCs) arising from transformed HSCs and carrying onco-
genic lesions such as BCR/ABL for chronic myelogenous
leukemia (CML) or activating Jak2 mutations for polycythemia
vera (PV), essential thrombocythosis, and primary myelofibrosis
(PMF) (Van Etten and Shannon, 2004; Levine andGilliland, 2008).
Deregulation of the BM microenvironment is another important
factor in the development of myeloid malignancies (Lane et al.,
2009). Genetic ablation of the retinoic acid receptor g (Rar-g)
or retinoblastoma (Rb) genes in BM stromal cells promotes
MPN development (Walkley et al., 2007a, 2007b), whereas inac-
tivation of the microRNA-processing enzyme dicer in immature
osterix (Osx)-expressing osteoprogenitors causes myelodys-
plastic syndrome (MDS) (Raaijmakers et al., 2010). In addition,
changes in the signaling activity of OBCs can alter HSC
numbers and cause lineage-specific defects in blood production
(Schepers et al., 2012). Recent evidence indicates that myeloid
malignancies also affect the function of the BM microenviron-
ment. In particular, decreased expression of Cxcl12 by BMtem Cell 13, 285–299, September 5, 2013 ª2013 Elsevier Inc. 285
Figure 1. HSC-Supportive Activity of Endosteal OBCs
(A) Flow cytometry approach used to identify endosteal BM stromal populations.
(B) Average numbers of ECs, MSCs, and OBCs contained in the endosteal (Lin/CD45) BM stromal fraction of WT mice (n = 23 in seven independent ex-
periments).
(C and D) Immunophenotype (C) and frequencies (D) of GFP+ endosteal ECs, MSCs, and OBCs in Osx-gfp, Cxcl12-gfp, and Nes-gfp reporter mice (n = 2–4 per
genotype; nd, not determined).
(E) Frequency of GFP+/hi cells in endosteal MSCs and OBCs of Osx-gfp, Cxcl12-gfp, and Nes-gfp reporter mice (green histograms). Gray histograms indicate
background GFP fluorescence levels in control populations.
(F) Schematic of the short-term coculture of HSCs with or without OBCs, and follow up analyses.
(legend continued on next page)
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MPN-Mediated Remodeling of the BM Nichestromal cells is observed in chronic-phase CML (Zhang et al,
2012), thereby impairing support for normal HSCs, whereas
severe osteoblastic defects are found in blast-crisis CML,
leading to a major loss of bone (Frisch et al., 2012). However,
much remains to be understood about how leukemic hematopoi-
esis impacts the BM microenvironment and, in turn, how
changes in the activity of specific BM niche cells contribute to
MPN pathogenesis. Here, we use an inducible Scl-tTA::TRE-
BCR/ABL double-transgenic mouse model of human chronic-
phase CML (Reynaud et al., 2011) to investigate the effect of
MPN development on the endosteal BM niche.
RESULTS
Endosteal OBCs Contain Cells with HSC-Supporting
Activity
Several flow cytometry approaches have been developed for
identifying endosteum-associated BM stromal cells. Here, we
used a previously described protocol to isolate ECs (Lin/
CD45/CD31+/Sca-1+), MSCs (Lin/CD45/CD31/CD51+/
Sca-1+), and OBCs (Lin/CD45/CD31/CD51+/Sca-1) from
hematopoietic cell-depleted, collagenase-treated crushed
bones of wild-type (WT) mice (Figures 1A and 1B) (Winkler
et al., 2010). In vitro characterization of these populations
showed the expected high frequency of colony-forming unit
fibroblast (CFU-F) activity and platelet-derived growth factor
receptor a (PDGFRa) levels in MSCs (Figures S1A and S1B avail-
able online). In contrast, OBCs had lower CFU-F frequencies and
PDGFRa levels, whereas ECs lacked PDGFRa expression and
were devoid of CFU-F activity. Consistent with their lineage
relationship, both MSCs and OBCs produced alkaline-
phosphatase-positive colonies and von Kossa-positive bone
nodules upon osteoblastic differentiation, with MSCs giving
rise to larger colonies than their OBC derivatives ( Figure S1A).
These results confirm reliable enrichment of endosteal MSCs
and their OBC derivatives using this flow-cytometry protocol.
We then used GFP reporter mice to determine the relationship
between endosteal subsets and BM niche cells with demon-
strated HSC-supportive activity. Strikingly, we found the pres-
ence of Osx+ osteoprogenitors, CXCL12hi CAR cells, and Nes+
MSC-like cells within the OBC fraction (Figures 1C and 1D),
with frequencies ranging from 10% in Osx-gfp and Cxcl12-
gfp mice to 70% in Nes-gfp mice (Figure 1E). As expected,
we also found that 35% of the MSC fraction was GFP+ in
Nes-gfp mice (Me´ndez-Ferrer et al., 2010), whereas less than
1%was GFP+/hi in eitherOsx-gfp orCxcl12-gfpmice (Figure 1E).
Additional flow-cytometry analyses of stromal versus hemato-
poietic BM cells (Figure S1C) and immunofluorescence analyses
of bone sections (Figure S1D) confirmed that most Osx-GFP+
cells were located at the bone surface, whereas Cxcl12-GFPhi
and Nes-GFP+ cells were found both at the bone surface and
throughout the BM cavity. These results indicate that the endos-
teal OBC fraction contains some of the previously described
HSC niche cells.(G) Cell numbers and methylcellulose CFU activity.
(H) Transplantation in lethally irradiatedWTCD45.1 recipients (n = 3–5mice per gro
every 4 weeks and analyzed for the percentage of CD45.2+ donor-derived cells
Data are means ± SD; *p% 0.05, **p% 0.01, ***p% 0.001. See also Figure S1.
Cell STo confirm that endosteal OBCs are able to maintain HSCs,
we performed short-term in vitro coculture experiments wherein
500 WT HSCs (Lin/c-Kit+/Sca-1+/Flk2/CD150+/CD48) were
grown for 4 days with or without 2,000 purified OBCs (Figure 1F).
As expected, HSCs cocultured with OBCs showed more in vitro
hematopoietic expansion and higher myeloid differentiation
potential in methylcellulose than HSCs cultured on plastic (Fig-
ure 1G). Mice transplanted with the progeny of 500 HSCs cocul-
tured with OBCs also displayed significantly higher levels of
donor chimerism than mice receiving cells cultured without
OBCs (Figure 1H). However, the chimerism level was still lower
than in mice transplanted with 500 freshly isolated WT HSCs,
indicating that OBCs were primarily maintaining HSC function
without increasing their numbers. In all cases, we observed
similar multilineage reconstitution (data not shown). These re-
sults directly demonstrate that phenotypically defined endosteal
OBCs have HSC-supporting activity.
MPN Development Causes Endosteal OBC Expansion
and Myelofibrosis Development
We then used our inducibleScl-tTA::TRE-BCR/ABL (BA) double-
transgenic mouse model of chronic-phase CML (Reynaud et al.,
2011) to address how MPN development affects the endosteal
BM niche. We first quantified the numbers of endosteal stromal
BM cells in age-matched littermate controls (Ctrl) and primary
diseased BA mice, which develop severe granulocytic expan-
sion within 5 to 6 weeks upon doxycycline withdrawal and
BCR/ABL induction (Figures 2A and 2B). Remarkably, we found
a large increase in OBC numbers in BAmice, with MSC numbers
remaining largely unaffected and EC numbers actually
decreasing (Figures 2C and S2A). This OBC expansion was
associated with an accumulation of myelofibrotic cells with
increased collagen deposition (Figure S2B), as previously
reported in both primary BA mice (Reynaud et al., 2011) and
human CML-affected patients (Thiele and Kvasnicka, 2006).
Although no significant changes in bone mineral density were
detected (data not shown), micro-computed-tomography ana-
lyses of proximal tibiae revealed increased trabecular thickening
of primary and secondary spongiosa and significant expansion
of the trabecular bone below the growth plate in BA mice (Fig-
ure S2C). Although trabecular numbers and spacing were
unchanged, trabeculae were thicker and showed increased con-
nectivity (Figure S2D). In contrast, cortical bone formation was
unaffected (Figure S2C), and tartrate-resistant acid phosphatase
(TRAP) staining showed no qualitative differences in osteoclast
numbers between Ctrl and BA mice (Figure S2E). To exclude
the possibility that BCR/ABLwas expressed in OBCs, we gener-
ated Scl-tTA::TetO-H2B-gfp double-transgenic reporter mice
(Figure S2F). Whereas some ECs (Le´cuyer and Hoang, 2004)
and all hematopoietic BM cells including HSCs were GFP+, no
cells within the OBC and MSC fractions expressed GFP. This
finding indicates that the Scl/Tal-1 30-enhancer element is not
active in endosteal MSCs and OBCs and rules out an intrinsic
effect of BCR/ABL expression in these populations. Theseup, with results replicated in another independent experiment). Mice were bled
( cult., no culture).
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Figure 2. MPN Hematopoiesis Induces Expansion of Endosteal OBCs
(A) Overall experimental design. Primary diseased Scl-tTA::TRE-BCR/ABL (BA) and age-matched control (Ctrl) mice were analyzed 6 weeks after doxycycline
(dox) withdrawal (n = 9–14 per group in four independent experiments). Purified CD45.2 HSCs (500– 4,000 cells) were transplanted into lethally irradiated WT
CD45.1 recipients (n = 10–13 mice per group in six independent experiments), and unfractionated CD45.2 BM cells (2 3 106 cells) into WT or Osx-gfp F1s
recipients (n = 3–6 mice per group in two independent experiments).
(B) Percentage of Gr-1+/Mac-1+ myeloid cells in the blood of primary Ctrl and BA mice.
(C) Numbers of endosteal ECs, MSCs, and OBCs in primary Ctrl and BA mice.
(D) Percentage of donor-derived Gr-1+/Mac-1+ myeloid cells in the BM and blood of Ctrl and BA HSC transplanted (tx) WT mice.
(E) Numbers of endosteal ECs, MSCs, and OBCs in Ctrl and BA HSC tx WT mice.
(legend continued on next page)
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MPN-Mediated Remodeling of the BM Nicheresults demonstrate that MPN development is accompanied by
a striking expansion of endosteal OBCs, an increase in trabec-
ular bone formation, and BM fibrosis.
To demonstrate that MPN development is directly responsible
for the OBC expansion, we transplanted purified HSCs isolated
from primary Ctrl and diseased BA mice into sublethally irradi-
ated WT recipients (Figure 2A). Mice that received BA HSCs all
developed CML within 3 to 5 months following transplantation
(Figure 2D). Remarkably, diseased BA HSC-transplanted WT re-
cipients also showedOBCexpansion, whichwas now accompa-
nied by an increase in MSC numbers and BM fibrosis (Figures 2E
and 2F). To test whether MPN-expanded OBCs are involved in
myelofibrosis development, we transplanted unfractionated
Ctrl or BA BM cells into lethally irradiated Osx-gfp recipients,
wherein10% of endosteal OBCs were marked by GFP expres-
sion (Figure 1E). Strikingly, diseased BA BM-transplanted
Osx-gfp recipients showed accumulation of GFP+ cells in the
BM cavity (Figure 2G), which reflected the contribution of
MPN-expanded recipient-derived Osx-GFP+ OBCs to the
myelofibrotic tissue. Collectively, these results indicate that
MPN progressively alters the architecture of the BM microenvi-
ronment and directly causes an expansion of endosteal OBCs
that, in turn, contribute to BM fibrosis.
MPN Myeloid Cells Stimulate MSCs to Overproduce
OBCs
To understand howMPN development leads to OBC expansion,
we developed an in vitro coculture/imaging approach modeling
the interactions between hematopoietic and stromal BM popula-
tions (Figure 3A). WT MSCs or OBCs were isolated from b-actin-
gfpmice and cocultured for up to 10 days with BM cells isolated
from Ctrl or BA mice. A combination of manual and software-
automated cell counting of fluorescencemicroscopy images ob-
tained with an IN Cell Analyzer 2000 was then used to determine
the number of MSC- or OBC-derived colonies and GFP+ cells
per colony. As expected, MSCs cocultured with BM cells
showed more numerous colonies than MSCs cultured without
hematopoietic cells (0.6 ± 0.7 versus 6.9 ± 3.2 colonies; n =
10; p % 0.001). In these conditions, BA BM cells significantly
increased the size of MSC-derived colonies compared to Ctrl
BM cells (Figure 3B), without changing the total numbers of col-
onies (6.9 ± 3.2 versus 6.5 ± 3.6 colonies; n = 10). In contrast, BA
BM cells had no effect on the size (Figure 3B) or the number of
OBC-derived colonies (3.7 ± 2.5 versus 4.0 ± 1.0 colonies; n =
10), hence demonstrating a specific effect of leukemic hemato-
poiesis on MSCs. Fluidigm-based gene analyses uncovered no
major differences in expression of the cell-cycle machinery in
MSCs and OBCs isolated from primary Ctrl and BA mice,
besides a significant decrease in Ccnd2 (cyclinD2) and p27
expression in BA populations (Figure S3A). EdU incorporation
experiments performed after 7 days of coculture showed that
BA BM cells directly increased the proliferation rates of expand-
ing MSC-derived cells (Figures 3C and S3B). Consistent with an
enhanced OBC differentiation, MSC-derived cells cocultured for(F) Masson’s trichrome staining of sternums from the indicated mice. Arrows ind
(G) Immunofluorescence analyses of sternums from Ctrl and BA BM tx WT andOs
GFP+ myelofibrotic cells. Scale bar represents 250 mm.
Data are means ± SD; *p% 0.05, **p% 0.01, ***p% 0.001. See also Figure S2.
Cell S10 days with BA BM cells also showed a smaller, more rounded
osteoblastic-like morphology and increased expression of early
osteoblastic differentiation markers as measured by quantitative
RT-PCR (qRT-PCR) analyses (Figures S3C and S3D). However,
upon differentiation, MPN-expanded OBCs did not maintain a
proliferative state, as shown in vivo by the absence of staining
with the proliferation marker Ki67 of recipient-derived Osx-
GFP+ OBCs (Figure S3E). These results indicate that MPN BM
cells directly stimulate MSCs to overproduce OBC derivatives.
We next tested the importance of leukemic myeloid cells for
OBC expansion. We first confirmed that mature BA BM cells,
rather than immature c-Kit+ stem and progenitor cells, were
responsible for the increase inMSC colony size (data not shown).
We then usedmagnetic bead depletion to obtainR 95%Mac-1+
myeloid-enriched BM cells from both Ctrl and BA mice (Fig-
ure 3D). Strikingly, we found that myeloid-enriched Ctrl BM cells
did not increaseMSCcolony size in contrast tomyeloid-enriched
BA BM cells, hence demonstrating the specific involvement of
leukemic myeloid cells. To address the reliance of OBC expan-
sion on leukemic myeloid cells, we re-exposed primary diseased
BAmice to doxycycline to block BCR/ABL expression and erad-
icate leukemic myeloid cells (Figure 3E). Following normalization
of myeloid counts, we observed a progressive decrease in OBC
numbers, with full recovery by 4 months post reinduction, and a
quick disappearance of myelofibrosis as early as 2 months post
reinduction (Figure 3F). These results are consistent with normal
turnover rates of MSCs (Park et al., 2012), and they demonstrate
that leukemic myeloid cells are both necessary and sufficient to
drive OBC expansion and to remodel the endosteal BM niche.
Both Soluble Factors and Direct Cell Contact Drive OBC
Expansion
To understand how leukemic myeloid cells stimulate MSCs to
overproduce OBC derivatives, we first used Transwell plates to
assess the relative contribution of secreted soluble factors
versus direct cell-cell interactions. Strikingly, we did not observe
a significant increase in MSC colony size whenBABM cells were
physically separated from MSCs (Figure 4A). Examination of
MSCs cocultured with myeloid-enriched BA BM cells also
showed close contacts between the two cell types throughout
the culture period (Figure S4A). These findings indicate that
direct contacts or close-proximity signals between leukemic
myeloid cells andMSCs are important in driving OBC expansion.
We then directly tested the effect of candidate factors known
to increase osteoblastic differentiation, such as interleukin-6 and
interleukin-1b (IL-6 and IL-1b) (Erices et al., 2002; Sonomoto
et al., 2012) or previously implicated in either leukemia-induced
stromal changes, such as the chemokine (C-C motif) ligand 3
(CCL3, also called MIP-1a) and granulocyte colony-stimulating
factor (G-CSF) (Frisch et al., 2012; Zhang et al., 2012), or myelo-
fibrosis development, such as TGF-b and thrombopoietin (TPO)
(Varricchio et al., 2009). Although both IL-6 and IL-1b levels were
increased in the serum of primary diseasedBAmice (Figure S4A)
(Reynaud et al., 2011; Zhang et al., 2012), neither of theseicate areas with myelofibrotic cells. Scale bar represents 250 mm.
x-gfpmice stained for DAPI (blue) and GFP (green). Arrows indicate areas with
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Figure 3. MPN Myeloid Cells Stimulate MSCs to Overproduce OBCs
(A) Schematic of the in vitro coculture/imaging approach. MSCs or OBCs isolated from b-actin-gfpmice were cultured with Ctrl orBABM cells and imaged for the
number of GFP+ cells per colony using an IN Cell Analyzer 2000. Representative images are of wells containing MSC- and OBC-derived GFP+ colonies after
10 days culture with Ctrl and BA BM cells. Scale bar represents 1 mm.
(B) Average numbers of GFP+ cells obtained per MSC or OBC colony after 10 days culture ± Ctrl or BA BM cells (n R 3 per group, with at least 11 individual
colonies scored per condition; nd, not determined).
(C) Frequencies of EdU+ cells in resorted MSC-derived GFP+ cells cultured with Ctrl or BA BM cells for 7 days and pulsed with 10 mM EdU for 3 hr (n = 7–8 per
group).
(D) Frequencies of hematopoietic cells stained with the indicated markers in unfractionated and myeloid-enriched (my) Ctrl and BA BMs, and average
numbers of GFP+ cells obtained per MSC colony after 10 days culture with Ctrl or BAmyBM cells (nR 3 per group, with at least 65 individual colonies scored per
condition).
(legend continued on next page)
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MPN-Mediated Remodeling of the BM Nichecytokines, nor tumor necrosis factor a (TNF-a), were able to
increase MSC colony size when added individually to the
cultures (Figure S4B). In addition, OBC expansion and myelofi-
brosis were still observed in primary BA mice lacking either Il-6
or Il-1r1 genes (Figures S4C and S4D), confirming that MPN-
mediated remodeling of the endosteal BM niche was largely
independent of the aberrant secretion of these proinflammatory
cytokines by leukemic myeloid cells. Among the other factors
tested, only TPO increased MSC colony size by itself (Fig-
ure 4B). Strikingly, addition of Ctrl BM cells significantly
potentiated the effect of TPO and CCL3 on MSC colony size,
but did not promote MSC expansion with either TGF-b or
G-CSF (Figure 4B). We also confirmed elevated levels of CCL3
and TPO in the BM plasma of primary diseased BA mice
and detected a trending increase in CCL3 and G-CSF levels in
the supernatant of MSC cocultures with BA BM cells (Figure 4D).
These results suggest that TPO and CCL3, in conjunction with
direct interactions between MSCs and leukemic myeloid cells,
drive the overproduction of OBC derivatives during MPN
development.
Molecular Features of MPN-Expanded OBCs
To determine whether MPN-expanded OBCs are functionally
altered, we compared the gene expression profiles of OBCs iso-
lated from primary Ctrl and diseased BA mice using Affymetrix
Gene ST 1.0 microarrays. Consistent with their identity, both
Ctrl and BA OBCs expressed high levels of osteoblast and
chondrocyte differentiation markers and low levels of MSC and
adipocyte differentiation genes, and they were not contaminated
by adherent myeloid cells (Figure S5A). Statistical analysis of mi-
croarrays uncovered 610 genes that were differentially ex-
pressed between Ctrl and BA OBCs (R1.5-fold; p % 0.05),
with 437 upregulated and 173 downregulated genes (Tables
S1 and S2). Gene ontology (GO) analyses of these genes identi-
fied processes such as extracellular matrix organization, regula-
tion of cell adhesion, and inflammatory responses as being
significantly enriched in BA OBCs (Figure 5A and Table S3). Ex-
amination of individual genes showed changes in extracellular
matrix components that are relevant for myelofibrosis develop-
ment, such as increased expression of chitinase (Chi3l1),
Spp1, and fibrinogen (Fgg) and decreased expression of several
types of collagens (Col), versican proteoglycans (Vcan), laminin
glycoproteins (Lamc1), and integrin ligands (Fbln5), as well as
increased expression of a whole range of matrix metallopepti-
dases (Mmp) and ADAM metallopeptidases (Adamts) that are
probably important for tissue remodeling (Figure 5B). BA OBCs
also displayed changes in integrin (Itg) and cadherin (Cdh)
expression levels, as well as a striking upregulation of the IL-1
superfamily of proinflammatory cytokines and many serum am-
yloids (Saa) (Figure 5B). These results were validated by subse-
quent qRT-PCR and Fluidigm-based gene expression analyses
(Figures S5B and S5C). Importantly, many of the genes upregu-
lated in primary BA OBCs were also upregulated in WT MSC-(E) Schematic of the in vivo MPN regression experiment. Primary diseased BA an
(+dox) to block BCR/ABL expression (n = 3–6 mice per group).
(F) Percentage of Gr-1+/Mac-1+ myeloid cells in the BM of re-exposed mice and
represents 100 mm.
Data are means ± SD; *p% 0.05, ***p% 0.001. See also Figure S3.
Cell Sderived cells cocultured withBABM cells (Figure S3A), thus con-
firming that thesemolecular changes were a direct consequence
of exposure to leukemic myeloid cells. Taken together, these re-
sults demonstrate the myelofibrotic, proinflammatory nature of
MPN-expanded OBCs.
We then took advantage of our Fluidigm-based gene
expression analyses to investigate changes in signaling activity
occurring in MPN-expanded OBCs (Figure 5D and Table S4).
We found evidence of elevated TGF-b signaling in BA OBCs as
shown by increased expression of the TGF-b targets Smad7,
Timp1, and Serpine. We also observed attenuated Notch
signaling in BA OBCs as evidenced by decreased expression
of both Notch1 and Notch2 receptors and Notch targets Hes1
and Hey2. In contrast, we found no consistent trend in the status
of the Wnt pathway, with decreased expression of the Lrp5
coreceptor, increased expression of Lef1 transcription factor,
and unchanged levels of the Wnt target Cy61. Moreover, we
confirmed active inflammatory signaling in BA OBCs, with
increased expression of IL-1 receptor (Il-1r1) and receptor
antagonist (Il-1rn) and upregulation of both TNF-a (Tnf) and
IkBa (Nfkbia). These results indicate that changes in TGF-b,
Notch, and inflammatory signaling are associated with the
remodeling of MPN-expanded OBCs into inflammatory myelofi-
brotic cells.
MPN-Expanded OBCs Have Compromised
HSC-Supportive Activity
Finally, we investigated whether MPN-expanded OBCs had
altered HSC-supportive activity toward either normal HSCs or
transformed LSCs. We performed short-term in vitro coculture
experiments wherein Ctrl or BA HSCs were grown for 4 days
with Ctrl or BAOBCs (Figure 6A). Although Ctrl HSCs cocultured
with either OBC population displayed similar in vitro hematopoi-
etic expansion and myeloid differentiation activity (Figures 6B),
transplantation experiments showed significantly impaired
donor chimerism in mice injected with the progeny of Ctrl
HSCs coculturedwithBAOBCs (Figures 6C). Defective reconsti-
tution was not the result of changes in lineage distribution
(Figure S6A), but was due to reduced numbers of engrafted
donor-derived Ctrl HSCs (Figure S6B). BA HSCs also displayed
similar hematopoietic expansion and myeloid differentiation
activity when cocultured with either OBC population (Figure 6D).
However, in sharp contrast to their normal counterparts, the
engraftment ability of BA HSCs was largely independent the
OBC population on which they were cocultured (Figures 6E
and S6C). In both cases, we observed either impaired engraft-
ment or CML development eventually leading to an early death,
which was consistent with previous findings showing poor
engraftment from freshly isolated BA HSCs (Zhang et al.,
2012). These results indicate that MPN-expanded OBCs are
severely compromised in their ability to maintain normal HSCs,
whereas transformed LSCs are essentially resistant to the detri-
mental effect of BA OBCs.d age-matched Ctrl mice were re-exposed for 2 or 4 months (m) to doxycycline
Masson’s trichrome staining of sternums from the indicated mice. Scale bar
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Figure 4. MSC Stimulation Requires TPO,
CCL3, and Direct Contact with MPNMyeloid
Cells
(A) Schematic and average numbers of GFP+ cells
obtained per MSC colony after 10 days coculture
without direct contact with Ctrl or BA BM cells in
24-well Transwell plates (n = 3 per group, with at
least 30 individual colonies scored per condition).
(B) Schematic and average numbers of GFP+ cells
obtained per MSC colony after 10 days cocul-
ture with the indicated recombinant cytokines
(50 ng/ml except for TGF-b used at 10 ng/ml) ± Ctrl
BM cells (n R 6 per group, with at least 20
individual colonies scored per condition).
(C) ELISA quantification of CCL3, TPO, and G-CSF
levels in the serum and BM plasma (BM) of primary
Ctrl and BA mice (n = 6–8 per group), and super-
natant (sup) from 10 day cocultures of MSCs with
Ctrl and BA BM cells (n = 3 per group; nd, not
detectable).
Data aremeans ± SD; *p% 0.05, ***p% 0.001. See
also Figure S4.
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MPN-Mediated Remodeling of the BM NicheWe then used our microarray results, as well as confirmatory
qRT-PCR and Fluidigm-based gene expression analyses, to
address the underlying mechanism (Figures 6F, 6G, and S6D).
We found a broad downregulation ofmany HSC retention factors
in BA OBCs compared to Ctrl OBCs, including Lepr, Cxcl12,
N-cadherin (Cdh2), Scf, Angpt1, and Slit2. We also observed a
striking shift in the expression pattern of TGF-b molecules in
BA OBCs, with downregulation of the quiescence-enforcing
Tgfb1 and massive upregulation of the myeloid-promoting
Tgfb2. These molecular changes are likely to contribute to the
impaired ability of MPN-expanded OBCs to maintain normal
HSCs and to favor MPN development. Collectively, these data
identify how an MPN-remodeled endosteal BM niche can favor
LSC function by impairing normal hematopoiesis and promoting
myeloid differentiation.
DISCUSSION
Transgenic mouse models of human MPNs provide an ideal
platform for understanding how leukemic hematopoiesis dis-
rupts the normal mechanisms controlling HSC function and
blood production. Previously, we found that aberrant secretion292 Cell Stem Cell 13, 285–299, September 5, 2013 ª2013 Elsevier Inc.of proinflammatory cytokines by leukemic
myeloid cells establishes a feedforward
loop that drives myeloid differentiation
and CML development by influencing
fate decisions in the leukemic multipotent
progenitor compartment (Reynaud et al.,
2011). Here, we show that leukemic
myeloid cells also remodel the endosteal
BM niche into a self-reinforcing leukemic
niche that impairs normal hematopoiesis,
favors LSC function, and contributes to
myelofibrosis development (Figure 7).
These results expand our understanding
of the effects of leukemic hematopoiesis
on the BM microenvironment and thecontribution of the endosteal BM niche to MPN pathogenesis.
Moreover, they identify a previously unrecognized mechanism
for the BM fibrosis and loss of normal hematopoiesis that often
accompanies MPN development in humans. Altogether, they
uncover a close interrelationship between leukemic hema-
topoiesis and the leukemic microenvironment, which could be
exploited for the development of new therapeutic strategies.
Previous lineage-tracking studies have identified various pop-
ulations of perivascular MSC-like cells and endosteal osteopro-
genitor cells as important BM niche cells for HSCs (Frenette
et al., 2013). In parallel, several flow cytometry approaches
have been developed for isolating and interrogating the function
of different endosteal BM stromal subsets. However, it remains
unclear how these two methodologies overlap in identifying
BM niche cells important for HSC activity. Here, we used a frac-
tionation method developed by the Levesque group to isolate
BM stromal populations enriched for endosteal MSCs (Lin/
CD45/CD31/CD51+/Sca-1+) and their OBC derivatives (Lin/
CD45/CD31/CD51+/Sca-1), which represents a mixture of
both immature and mature osteoblasts (Winkler et al., 2010).
We show that such phenotypically defined OBC population con-
tains cells known from lineage-tracking studies to be important
Figure 5. Molecular Features of MPN-
Expanded OBCs
(A) OBCs were purified from individual primary Ctrl
and BA mice (n = 5 per group) and used for
microarray analyses. Histogram shows the GO
results for the biological processes significantly
affected in BA OBCs.
(B) Microarray results detailing the genes involved
in extracellular matrix organization, regulation of
cell adhesion, and inflammatory response. Data
are expressed as log2 fold relative to the average
expression level in Ctrl OBCs (set to 0).
(C) Fluidigm-based gene expression analyses of
TGF-b, Notch, Wnt, and inflammation pathway
components in MSCs and OBCs isolated from
primary Ctrl andBAmice (n = 4–6 pools of 100 cells
per population). Data are expressed as log2 fold
relative to the average level in Ctrl MSCs (set to 0).
Bars indicate average levels, and /* statistical
differences between Ctrl versus BA MSCs and
OBCs, respectively.
Data are means ± SD; *p % 0.05, **p % 0.01,
***p% 0.001. See also Figure S5.
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some CXCL12hi CAR cells, and a large fraction of Nes+ MSC-
like cells. We also found that the phenotypically defined endos-
teal MSC fraction contains Nes+MSC-like cells, and we are now
interested in extending these cross-identification approaches to
the recently described perivascular Lepr+,Mx1+, or Prx1+ MSC-
like cells (Ding et al., 2012; Park et al., 2012; Greenbaum et al.,
2013). Using a series of in vitro coculture assays followed by
imaging and transplantation approaches, we confirm the ability
of endosteal MSCs to give rise to OBCs and, most importantly,
directly demonstrate the HSC-supportive capability of endosteal
OBCs. Our results indicate that HSC niche cells are also present
at the bone surface, a finding that reinforces a role for the
endosteal BM niche in controlling HSC maintenance and blood
production.
Recent studies indicate that dysfunctional BM microenviron-
ments contribute to the development of myeloid malignancies
and that, in turn, leukemic hematopoiesis can create dysfunc-
tional BM microenvironments. Here, we asked whether MPN
development could impact the activity of the endosteal BMCell Stem Cell 13, 285–299, Sniche. Through analyses of primary BA
mice and LSC-transplanted WT mice, we
show that MPN development results in a
massive expansion of endosteal OBCs
associated with increased trabeculation
and trabecular thickening. These features
contrast with the severe osteoblastic de-
fects and bone loss reported in a CML
blast-crisis mouse model (Frisch et al.,
2012) and are likely to reflect fundamental
and clinically relevant differences be-
tween chronic MPN and transformed
acute myeloid leukemia (AML). We
confirm that MPN-mediated OBC ex-
pansion is not restricted to BCR/ABLexpression, because it is also observed in junB-deficient mice
(Figure S7), which develop aCML-likeMPNwith high penetrance
(Santaguida et al., 2009). Moreover, using a combination of
in vitro and in vivo approaches, we demonstrate that MPN-medi-
ated OBC expansion is driven by MSCs that are stimulated by
leukemic myeloid cells to proliferate and overproduce OBC de-
rivatives. This involvement of MSCs is in line with their high
expansion capability as compared to the restricted growth po-
tential of OBCs (Park et al., 2012). This function of leukemic
myeloid cells is also consistent with the newly described role of
monocytes and macrophages in regulating the activity of BM
niche cells and maintenance of HSCs (Frenette et al., 2013).
Althoughwedid not characterizeMPNmyeloid cells beyond their
broad expression of Mac-1, it is possible that they could contain
the leukemic and aberrantly behaving equivalents of the recently
described CD169+ macrophages (Chow et al., 2011) or F4/80+
osteomacs lining the endosteum (Chang et al., 2008; Winkler
et al., 2010). Altogether, our results show that MPN development
alters the normal activity of MSCs and their OBC derivatives,
leading to a major remodeling of the endosteal BM niche.eptember 5, 2013 ª2013 Elsevier Inc. 293
Figure 6. Impaired HSC-Supportive Activity of MPN-Expanded OBCs
(A) Schematic of the short-term coculture of Ctrl or BA HSCs with Ctrl or BA OBCs, and follow up analyses.
(B–E) Cell numbers and methylcellulose CFU activity for the progeny of Ctrl HSCs (B) or BA HSCs (D) cocultured with Ctrl or BA OBCs. Transplantation ex-
periments for the progeny of Ctrl HSCs (C) orBAHSCs (E) coculturedwith Ctrl orBAOBCs (n = 3–5mice per group, with results replicated in another independent
experiment).
(F) qRT-PCR-based gene expression analyses of HSC-regulatory molecules in OBCs isolated from individual primary Ctrl andBAmice (n = 3 per group). Data are
expressed as fold relative to the average expression level in Ctrl OBCs (set to 1).
(legend continued on next page)
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MSC growth and to control osteoblastic differentiation (Long,
2012). Here, we took advantage of our in vitro coculture/imaging
approach to demonstrate the importance of direct cell-cell inter-
actions between leukemic myeloid cells and expanding MSCs,
as well as to screen for the involvement of candidate factors
known to affect OBC production or myelofibrosis development.
Although BA myeloid cells exhibit aberrant secretion of proin-
flammatory cytokines known to increase osteoblastic differenti-
ation, we show that neither IL-6 nor IL-1b or TNF-a are involved in
MSC stimulation. We also exclude a direct role for G-CSF and
TGF-b, despite their importance for osteoblastic differentiation
and myelofibrosis development. On the other hand, we show
that both TPO, the physiologic regulator of platelet production
and a strong inducer of myelofibrosis (Varricchio et al., 2009),
and CCL3, an inflammatory chemokine that regulates MSC
migration and osteoblastic differentiation (Sordi et al., 2005; Val-
let et al., 2011), synergistically expand MSCs, especially when
BM cells are directly in contact with the cultured MSCs. Given
that both TPO and CCL3 levels are elevated in the BM plasma
of BA mice, they are probably part of the mechanism by which
leukemic myeloid cells stimulate MSCs to overproduce OBC
derivatives during MPN development. However, it is clear that
other soluble or membrane-bound factors expressed by
leukemic myeloid cells also contribute to this process. Our
results support the idea that a complex interplay in the BM cavity
between secreted soluble factors and direct interactions
between myeloid cells and MSCs controls the rate of OBC pro-
duction in both normal and disease conditions. They suggest
that distinct deregulations in this finely tuned equilibrium could
result in OBC expansion during MPN development and OBC
loss during AML development.
MPNs, unlike AML, often progress to BM fibrosis prior to
leukemic transformation, and the development of myelofibrosis
can have severe consequences even at the preleukemic stage
(Abdel-Wahab and Levine, 2009). Here, we show that MPN-
expanded OBCs accumulate in the BM cavity as inflammatory
myelofibrotic cells (Figure 7). We find clear evidence of myelofi-
brosis in both primary BA mice and LSC-transplanted WT mice
and demonstrate that MPN-expanded OBCs can directly
contribute to the myelofibrotic tissue in LSC-transplanted Osx-
gfp reporter mice. Furthermore, we show that OBCs, either
directly isolated from primary diseased BA mice or generated
in vitro by coculture of WT MSCs with BA BM cells, display
the molecular hallmarks of inflammatory myelofibrotic cells,
including changes in the expression of genes involved in cellular
adhesion, extracellular matrix remodeling, and inflammation.
Strikingly, many of the upregulated genes in MPN-expanded
OBCs are also elevated in human patients with rheumatoid and
osteoid arthritis (Okamoto et al., 2008). This convergence sug-
gests a tantalizing but still unexplored link between chronic
inflammatory diseases and MPN-associated myelofibrosis.
Given that MPN-expanded OBCs also express higher levels of
proinflammatory factors, they may directly contribute to the(G) Fluidigm-based gene expression analyses of members of the TGF-b family in
cells per population). Data are expressed as log2 fold relative to the average leve
differences between Ctrl versus BA OBCs.
Data are means ± SD; *p% 0.05; **p% 0.01. See also Figure S6.
Cell Soverproduction of leukemic myeloid cells, thus enforcing
a vicious cycle that perpetuates MPN development and
OBC expansion (Figure 7). Pathway-directed gene expression
analyses implicate increased TGF-b and inflammatory signaling
and attenuated Notch signaling as potential contributors to the
remodeling of MPN-expanded OBCs into inflammatory mye-
lofibrotic cells. It is therefore tempting to speculate that proin-
flammatory factors secreted by either leukemic myeloid cells
or MPN-expanded OBCs, together with tissue-remodeling
factors produced by the expanded OBCs, could create positive
feedback loops driving this process, similar to the interplay be-
tween IL-1b and serum amyloids described in rheumatoid
arthritis (Okamoto et al., 2008).
Myelofibrosis is a prominent feature of PV and PMF MPNs
(Abdel-Wahab and Levine, 2009) and is observed in 30% of
patients with chronic-phase CML, where it is often associated
with poor-prognosis disease and progression to blast crisis
(Thiele and Kvasnicka, 2006). Myelofibrosis in PV and PMF
MPNs has been linked to defective megakaryopoiesis, and
impaired megakaryopoiesis can result in the development of
PV- and PMF-like MPNs in mice (Varricchio et al., 2009). In
contrast, we never observed any defects in megakaryopoiesis
in CML mouse models, including BA and junB-deficient mice
(data not shown). Here, we identify a previously unrecognized
route for the pathogenesis of BM fibrosis associated with
CML-like MPNs that involves leukemic myeloid cells driving
the expansion and remodeling of endosteal OBCs (Figure 7).
We show that both OBC expansion and myelofibrosis develop-
ment depend on the presence of leukemic myeloid cells and
can be fully reverted upon blockade of BCR/ABL expression
and recovery of normal hematopoiesis. This is consistent with
the reduction in fibrosis observed in CML-affected patients suc-
cessfully treated with tyrosine kinase inhibitors (Thiele and Kvas-
nicka, 2006), which reinforces the idea that a similar mechanism
could be operating in humans. It will now be important to directly
address its contribution to fibrosis occurring in patients with
CML, as well as in patients with PV and PMF, given that overpro-
duction of leukemic myeloid cells is also observed in these other
MPN diseases (Abdel-Wahab and Levine, 2009). Our results
implicate remodeling of the endosteal BM niche by leukemic
myeloid cells as an important mechanism for BM fibrosis associ-
ated with MPN development.
Loss of normal hematopoiesis is another event occurring in
human MPNs and during the development of most leukemias,
for reasons that still remain largely unknown. Here, we show
that leukemic hematopoiesis turns the endosteal BM niche into
a leukemic niche, which promotes LSC function and impairs
the maintenance of normal HSCs (Figure 7). We find altered
expression of many HSC-regulatory genes in MPN-expanded
OBCs, including a broad downregulation of essential HSC reten-
tion factors (i.e., Cxcl12, Scf, Lepr, Angpt1, Cdh2, Slit2, and
Tgfb1) and upregulation of factors promoting myeloid differenti-
ation (i.e., Il1b and Tgfb2). We directly show that MPN-expanded
OBCs exhibit reduced ability to maintain HSCs, which mainlyMSCs and OBCs isolated from primary Ctrl and BAmice (n = 4–6 pools of 100
l in Ctrl MSCs (set to 0). Bars indicate average levels, and * indicates statistical
tem Cell 13, 285–299, September 5, 2013 ª2013 Elsevier Inc. 295
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MPN-Mediated Remodeling of the BM Nicheaffects normal HSCs, with minimal effects on transformed LSCs.
The molecular changes we uncovered are probably responsible
for the compromised HSC-supportive activity of the remodeled
OBCs, especially with respect to decreased Cxcl12 expression,
which could directly contribute to loss of normal HSCs through
increased mobilization to the periphery (Zhang et al., 2012;
Greenbaum et al., 2013). Molecular changes in MPN-expanded
OBCs are also likely to promote MPN development by favoring
myeloid differentiation and overproduction of leukemic myeloid
cells from LSCs. The fact that LSC maintenance is unaffected
by the remodeled OBCs could be, in large part, due to their
different requirement in adhesion molecules for homing and
retention in the BM compared to normal HSCs (Gordon et al.,
1987; Krause et al., 2006). The loss of normal HSCs also prob-
ably contributes to the clonal dominance of BCR/ABL-express-
ing LSCs in transplantedmice (Reynaud et al., 2011) and patients
with CML (Holyoake et al., 1999). Moreover, such differential
retention provided by a remodeled BM microenvironment could
explain clonal dominance in situations where transformed
HSCs have impaired functions, such as in MDS and BM-failure
syndromes (Levine and Gilliland, 2008). Taken together, our
results unveil additional features of MPN pathogenesis and
uncover how leukemic myeloid cells create a self-reinforcing
leukemic BM niche that promotes MPN development at the
expense of normal hematopoiesis. Targeting this pathological
interplay could represent a novel therapeutic avenue for the
treatment of MPN-affected patients and prevention of myelofi-
brosis development.
EXPERIMENTAL PROCEDURES
Supplemental Experimental Procedures can be found in Supplemental
Information.
Mice
All the genetic models were previously published. Irradiation and trans-
plantation procedures were performed as previously described (Reynaud
et al., 2011). All mice were maintained at the University of California, San
Francisco (UCSF) in accordance with Institutional Animal Care and Use
Committee-approved protocols.
Bone Analyses
Masson’s trichrome staining was performed as described (Reynaud et al.,
2011). Bones for immunofluorescence imaging were stained with a rabbit
anti-Ki67 primary (SP6 NeoMarkers) followed by a goat anti-rabbit-A594
secondary (Invitrogen) antibody and counterstained with DAPI. Images were
taken on an IN Cell Analyzer 2000 (GE Healthcare).
Stromal and Hematopoietic Cell Analyses
Staining and enrichment procedures for flow cytometry were performed as
described (Reynaud et al., 2011; Schepers et al., 2012). Myeloid-enriched
BM cells were obtained by depleting the BM of lineage-positive cells using
purified rat anti-mouse antibodies and anti-rat Dynal beads. TPO, CCL3,Figure 7. Model for the Leukemic BM Niche
The endosteal BM niche contributes to HSC maintenance and regulated produ
probably contributes to regulated production of bone-lining OBCs from MSCs. D
leukemic myeloid cells that secrete high levels of proinflammatory cytokines, thus
panel). Leukemic myeloid cells also directly stimulate MSCs to overproduce fu
myelofibrotic cells. These MPN-expanded OBCs are severely compromised in th
differentiation. Our results demonstrate that MPN development remodels the e
hematopoiesis, favors LSC function, and contributes to BM fibrosis. See also Fig
Cell Sand G-CSF protein levels were measured by ELISA according to the manufac-
turer’s instructions (R&D Systems and RayBiotech).
Cell-Culture Experiments
Short-term coculture experiments were performed as previously described
(Schepers et al., 2012), with each well containing the progeny of 500 HSCs
treated as follows: 5% of the cells were used to measure cell numbers and
plated at various dilutions in methylcellulose, and 95% of the cells were trans-
planted in lethally irradiated mice with helper BM cells. Coculture/imaging ex-
periments were carried out in a-modified Eagle medium containing 10% fetal
bovine serum, 13 penicillin and streptomycin, and 50mM 2-mercaptoethanol.
Unfractionated or myeloid-enriched BM cells were seeded with stromal BM
cells isolated from b-actin-gfpmice in 96-well or 24-well Transwell plates. Cells
were cocultured without medium replacement, and recombinant cytokines
were refreshed every 2–3 days. EdU labeling experiments were performed
after 7 days of coculture. Stromal-derived GFP+ cells were imaged on an IN
Cell Analyzer 2000 every 2–3 days, and automated counting was used to
enumerate the total number of GFP+ cells per condition after 10 days of cocul-
ture. The number of colonies (R20 cells) was determinedmanually and used to
calculate the average number of cells per colony.
Gene-Expression Analyses
Analyses using the Fluidigm 96.96 Dynamic Array IFC platform and qRT-PCR
analyses were performed as previously described (Reynaud et al., 2011;
Santaguida et al., 2009). For qRT-PCR and microarray analyses, RNA was
purified using the Arcturus PicoPure RNA Isolation Kit, amplified using the
NuGEN Pico WTA kit, and cleaned using the QIAGEN QIAquick PCR Purifica-
tion Kit according to manufacturers’ instructions. For microarray analyses,
sense-strand complementary DNA targets were generated using the NuGEN
WT-Ovation Exon Module, fragmented, biotinylated using the NuGEN
Encore Biotin Module, and hybridized on Affymetrix Gene ST 1.0 microarrays
according to manufacturers’ instructions.
Statistical Analyses
p values were calculated using the unpaired Student’s t test, and differences
with p% 0.05 were considered statistically significant.
ACCESSION NUMBERS
Raw and normalized expression data have been deposited in the Gene
Expression Omnibus under accession number GSE48438.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.stem.2013.06.009.
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